Analysis of Concomitant Medications and Comorbidities in Patients Received PN and Experienced ADRs = Analysis of Concomitant Medications and Comorbidities in Patients Received PN and Experienced ADRs

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate frequently used medications and comorbidities among patients who experienced adverse drug reactions (ADR) while receiving parenteral nutrition (PN).
Methods: Korean Adverse Event Reporting System (KAERS) database from 2015 was used for analysis. Adult patients (≥19 years old) who received PN and experienced ADRs were included. The following five specific agents in PN were identified to be causative agents: amino acids, fat emulsions, carbohydrates, combinations and solutions for PN. These agents were classified as “certain,” “probable,” or “possible” to cause ADRs in corresponding patients based on the WHO-Uppsala Monitoring Centre criteria.
Results: We evaluated total of 1,529 ADRs from 1,036 patients. Mean patient age was 57 (±15.6) and mean number of ADRs per patient was 1.5 (±0.7). Frequently reported concomitant agents were opioids (60 cases, 13.0%), other betalactam antibacterials (45 cases, 9.8%), drugs for peptic ulcer and GERD (42 cases, 9.1%), non-steroid antiinflammatory and antirheumatic products (33 cases, 7.2%) followed by propulsives (12 cases, 2.6%), other analgesics and antipyretics (12 cases, 2.6%), and other antibacterials (12 cases, 2.6%). The leading frequent comorbidities were malignancy (416 cases, 33.0%), diseases of the digestive systems (96 cases, 7.6%), diseases of circulatory system (80 cases, 5.3%), injury, poisoning and certain other consequences of external causes (77 cases, 6.1%), diseases of musculoskeletal system and connective tissue (73 cases, 5.8%), and endocrine, nutritional and metabolic diseases (72 cases, 5.7%).
Conclusion: Our study showed that opioid was the most frequently used concurrent medication in patients who experienced ADRs while on PN. The most frequent comorbidity was malignancy. Patients who will be receiving PN with these concurrent medications or comorbidities may need more stringent monitoring for ADRs.